Skip to main content
. 2020 May 15;10(5):769. doi: 10.3390/biom10050769

Figure 3.

Figure 3

SF102 and SF134 repress viability in various cancer entities. Ovary (OVM), prostate (PC3), breast (BT-20), colorectal (SW707), glioblastoma (A172), hepatocellular (HepG2), neuroblastoma (IMR5), and T cell leukemia (Jurkat) cell lines were treated with SF101 or SF102 in concentrations of 10 µM and 30 µM. After 24 h, the viability was measured by MTT assay. DMSO served as a vehicle control. Data are means ±SD of at least three independent experiments. * p < 0.05, ** p < 0.01.